Publication: 2290

Publication: 2290

Randomized Phase II Study of Everolimus Alone (E) versus Everolimus plus Bevacizumab (E+B) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors, CALGB 80701 (Alliance)

URL

URL

Google Scholar

Citation:: J Clin Oncol vol 33 (suppl) abstr 4005

Meeting Instance:: ASCO 2015
Year:: 2015
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3473

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, CA31946, CA025224

Corr. Author:: Matthew Kulke
Authors:: Matthew H. Kulke Donna Niedzwiecki Nathan R. Foster Bryant Fruth Pamela L. Kunz Hagen Kennecke Edward M. Wolin Alan P. Venook

Networks:: CA824, LAPS-CT018, LAPS-MA036, LAPS-MN026, NY021, OR013

Study: CALGB-80701
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: